Comparison of prostate cancer survival in Germany and the <scp>USA</scp> : can differences be attributed to differences in stage distributions?

Abstract

The survival increase in Germany and the survival advantage in the USA might be explained by differences in incidence and stage distributions over time and across countries. Effects of early detection or a lead-time bias due to the more widespread utilisation and earlier introduction of PSA testing in the USA are likely to explain the observed patterns.